Indivior Drug Patent Portfolio

Indivior owns 4 orange book drugs protected by 31 US patents Given below is the list of Indivior's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11458091 Compositions and methods for the treatment of opioid overdose 10 Jul, 2038
Active
US10646484 Methods to treat opioid use disorder 22 Jun, 2038
Active
US11000520 Buprenorphine dosing regimens 06 Nov, 2035
Active
US11839611 Buprenorphine dosing regimens 06 Nov, 2035
Active
US8921387 Injectable flowable composition comprising buprenorphine 06 Jan, 2032
Active
US8975270 Injectable flowable composition comprising buprenorphine 05 Sep, 2031
Active
US10558394 Injectable flowable composition comprising buprenorphine 25 Jun, 2031
Active
US10198218 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
Active
US10592168 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
Active
US9272044 Injectable flowable composition buprenorphine 06 Jun, 2031
Active
US9498432 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
Active
US9782402 Injectable composition comprising buprenorphine 06 Jun, 2031
Active
US9827241 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
Active
US8475832 Sublingual and buccal film compositions 26 Mar, 2030
Active
US11135216 Sublingual and buccal film compositions 07 Aug, 2029
Active
US9687454 Sublingual and buccal film compositions 07 Aug, 2029
Active
US10010612 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
Active
US10376590 Sustained delivery formulations of risperidone compound 13 Feb, 2028
Active
US11013809 Sustained delivery formulations of risperidone compound 13 Feb, 2028
Active
US11712475 Sustained delivery formulations of risperidone compound 13 Feb, 2028
Active
US9180197 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
Active
US9186413 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
Active
US11110093 Sustained release small molecule drug formulation 05 Nov, 2026
Active
US10058554 Sustained release small molecule drug formulation 26 Sep, 2026
Active
US9597402 Sustained release small molecule drug formulation 26 Sep, 2026
Active
US10406160 Sustained release small molecule drug formulation 26 Jun, 2026
Active
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024 Expired
US8017150 Polyethylene oxide-based films and drug delivery systems made therefrom 13 Feb, 2023 Expired
US10285910 Sublingual and buccal film compositions 11 Oct, 2022 Expired
US9855221 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022 Expired
US9931305 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 14 Feb, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Indivior.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 16 May, 2024 US9498432
Recordation of Patent eGrant 12 Dec, 2023 US11839611
Recordation of Patent Grant Mailed 12 Dec, 2023 US11839611
Email Notification 12 Dec, 2023 US11839611
Patent Issue Date Used in PTA Calculation 12 Dec, 2023 US11839611
Mail Patent eGrant Notification 12 Dec, 2023 US11839611
Patent eGrant Notification 12 Dec, 2023 US11839611
Email Notification 23 Nov, 2023 US11839611
Issue Notification Mailed 22 Nov, 2023 US11839611
Dispatch to FDC 07 Nov, 2023 US11839611
Application Is Considered Ready for Issue 07 Nov, 2023 US11839611
Issue Fee Payment Received 31 Oct, 2023 US11839611
Issue Fee Payment Verified 31 Oct, 2023 US11839611
Payment of Maintenance Fee, 4th Year, Large Entity 30 Oct, 2023 US10646484
Payment of Maintenance Fee, 4th Year, Large Entity 08 Sep, 2023 US10592168


Indivior's Drug Patent Litigations

Indivior's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 20, 2014, against patent number US8475832. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with RB Pharmaceuticals Limited as the respondent. Click below to track the latest information on how companies are challenging Indivior's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9687454 November, 2018 FWD Entered
(02 Jun, 2020)
Indivior UK Limited Dr. Reddy’s Laboratories S.A.
US9687454 November, 2018 Terminated-Denied
(03 Jun, 2019)
Indivior UK Limited Dr. Reddy's Laboratories S.A.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Par Pharmaceutical, Inc.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Dr. Reddy’s Laboratories, Inc.
US8603514 November, 2016 Terminated-Settled
(06 Oct, 2017)
MonoSol Rx, LLC et al. Mylan Technologies, Inc. et al.
US8017150 May, 2016 Terminated-Denied
(05 Dec, 2016)
MonoSol Rx, LLC Dr. Reddy’s Laboratories, Inc.
US8603514 May, 2016 Terminated-Denied
(05 Dec, 2016)
MonoSol Rx, LLC Dr. Reddy's Laboratories, Inc.
US8475832 May, 2016 Terminated-Denied
(02 Dec, 2016)
Indivior UK Limited Dr. Reddy’s Laboratories, Inc.
US8475832 December, 2015 Terminated-Denied
(10 Jun, 2016)
Indivior UK Limited Teva Pharmaceuticals USA, Inc.
US8017150 December, 2015 Terminated-Denied
(23 May, 2016)
MONOSOL RX, LLC Teva Parmaceuticals USA Inc.
US8603514 December, 2015 Terminated-Denied
(23 May, 2016)
MONOSOL RX LLC Teva Pharmaceuticals USA Inc
US8475832 January, 2014 FWD Entered
(30 Jun, 2015)
RB Pharmaceuticals Limited BioDelivery Sciences International, Inc.
US8475832 June, 2014 Terminated-Denied
(19 Dec, 2014)
RB Pharmaceuticals Limited BioDelivery Sciences International, Inc.


Indivior Drug Patents' Oppositions Filed in EPO

Indivior drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15828368A Mar, 2021 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP11728037A Oct, 2018 Teva Pharmaceutical Industries Ltd. Opposition rejected
EP10740493A Oct, 2016 LTS LOHMANN Therapie-Systeme AG Patent maintained as amended
EP08725543A Oct, 2016 Lecomte & Partners Opposition rejected
EP11157819A Jun, 2014 Ahrens, Gabriele Patent maintained as amended
EP11162857A Apr, 2014 Generics [UK] Limited Granted and Under Opposition
EP02782151A Jun, 2013 Acino Pharma AG Revoked
EP02782151A Jun, 2013 Germann, Sandra Revoked
EP02801042A Sep, 2012 Ahrens, Gabriele Patent maintained as amended
EP02801042A Sep, 2012 LTS LOHMANN Therapie-Systeme AG Patent maintained as amended


Indivior's Family Patents

Indivior drugs have patent protection in a total of 37 countries. It's US patent count contributes only to 42.2% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Indivior Drug List

Given below is the complete list of Indivior's drugs and the patents protecting them.


1. Opvee

Opvee is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11458091 Compositions and methods for the treatment of opioid overdose 10 Jul, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opvee's drug page


2. Perseris Kit

Perseris Kit is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10010612 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
(3 years from now)
Active
US10376590 Sustained delivery formulations of risperidone compound 13 Feb, 2028
(3 years from now)
Active
US11013809 Sustained delivery formulations of risperidone compound 13 Feb, 2028
(3 years from now)
Active
US11712475 Sustained delivery formulations of risperidone compound 13 Feb, 2028
(3 years from now)
Active
US9180197 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
(3 years from now)
Active
US9186413 Sustained delivery formulations of risperidone compounds 13 Feb, 2028
(3 years from now)
Active
US11110093 Sustained release small molecule drug formulation 05 Nov, 2026
(2 years from now)
Active
US10058554 Sustained release small molecule drug formulation 26 Sep, 2026
(1 year, 11 months from now)
Active
US9597402 Sustained release small molecule drug formulation 26 Sep, 2026
(1 year, 11 months from now)
Active
US10406160 Sustained release small molecule drug formulation 26 Jun, 2026
(1 year, 8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Perseris Kit's drug page


3. Sublocade

Sublocade is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10646484 Methods to treat opioid use disorder 22 Jun, 2038
(13 years from now)
Active
US11000520 Buprenorphine dosing regimens 06 Nov, 2035
(11 years from now)
Active
US11839611 Buprenorphine dosing regimens 06 Nov, 2035
(11 years from now)
Active
US8921387 Injectable flowable composition comprising buprenorphine 06 Jan, 2032
(7 years from now)
Active
US8975270 Injectable flowable composition comprising buprenorphine 05 Sep, 2031
(6 years from now)
Active
US10558394 Injectable flowable composition comprising buprenorphine 25 Jun, 2031
(6 years from now)
Active
US10198218 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
(6 years from now)
Active
US10592168 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
(6 years from now)
Active
US9272044 Injectable flowable composition buprenorphine 06 Jun, 2031
(6 years from now)
Active
US9498432 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
(6 years from now)
Active
US9782402 Injectable composition comprising buprenorphine 06 Jun, 2031
(6 years from now)
Active
US9827241 Injectable flowable composition comprising buprenorphine 06 Jun, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sublocade's drug page


4. Suboxone

Suboxone is protected by 8 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8475832 Sublingual and buccal film compositions 26 Mar, 2030
(5 years from now)
Active
US11135216 Sublingual and buccal film compositions 07 Aug, 2029
(4 years from now)
Active
US9687454 Sublingual and buccal film compositions 07 Aug, 2029
(4 years from now)
Active
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 03 Apr, 2024
(6 months ago)
Expired
US8017150 Polyethylene oxide-based films and drug delivery systems made therefrom 13 Feb, 2023
(1 year, 7 months ago)
Expired
US10285910 Sublingual and buccal film compositions 11 Oct, 2022
(1 year, 11 months ago)
Expired
US9855221 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions 14 Feb, 2022
(2 years ago)
Expired
US9931305 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions 14 Feb, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suboxone's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List